Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics has been granted a U.S. patent for its CORE-NK platform technology, a significant milestone for the company’s cell therapy assets, including a universal NK cell asset and multiple preclinical-stage NK cell assets, with protection extending until 2039. The patent underscores the company’s commitment to developing innovative cell therapies for cancer and other diseases, bolstering its intellectual property portfolio in the vital U.S. biopharmaceutical market. Chimeric’s diversified portfolio features clinical and preclinical programs across various oncology disease areas, with ongoing clinical trials and more planned for 2024.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
